Harmonic (HLIT) Stock

Two Wheels Motor Racing selects Harmonic's solution to deliver high quality video streaming experience to motor racing enthusiasts.

This Industry Outlook article has featured Arista Networks, Corning, and Harmonic.

SAN JOSE, Calif. , Nov. 26, 2024 /PRNewswire/ -- Harmonic (NASDAQ: HLIT) today announced that Nimrod Ben-Natan, President and CEO of Harmonic, and Walter Jankovic, Harmonic's Chief Financial Officer, will participate in a fireside chat at the Raymond James 2024 TMT and Consumer Conference in New York City, on Monday, December 9, 2024 at 8:20 a.m.

SAN FRANCISCO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that Chris Murphy, Chief Financial and Business Officer, will participate in a fireside chat at the 7th Annual Evercore HealthCONx Conference on Wednesday, December 4, 2024, at 9:35 a.m.

NAPLES, Fla.--(BUSINESS WIRE)--Romanesque Capital Management, LLC (collectively with its affiliates, “Romanesque Capital”), which is a long-term shareholder of Harmonic, Inc. (NASDAQ: HLIT), today issued the following statement regarding its support of a strategic review aimed at a sale to maximize shareholder value: “We have long held high conviction in Harmonic's market leading products, valuable partnerships and disruptive innovation, having been invested since 2016. Despite these tailwinds,.

THB335 Phase 1 SAD/MAD clinical trial on track to deliver clinical results in 1Q'25 Strong financial position with cash and cash equivalents totaling $296.1 million  as of September 30, 2024 SAN FRANCISCO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory and gastrointestinal inflammatory diseases, today announced financial results for the third quarter September 30, 2024. “As the Phase 1 clinical trial of our development candidate THB335 continues toward an anticipated data readout in the first quarter of 2025, we are also making excellent progress in preparing to move efficiently into a Phase 2 clinical trial in chronic spontaneous urticaria,” said Natalie Holles, Chief Executive Officer at Third Harmonic Bio.

Harmonic Inc. posted strong Q3 results with a Non-GAAP EPS of $0.26 and revenue of $195.76 million, driven by Broadband's DOCSIS 4.0 rollout. Despite growth, concerns include project delays, heavy reliance on major clients, and potential profit margin flattening, leading to a cautious outlook. Video segment profitability improved, but revenue dipped slightly; financials show strong cash position but expect margin fluctuations and inventory increases.

Harmonic Inc. (NASDAQ:HLIT ) Q3 2024 Earnings Conference Call October 28, 2024 5:00 PM ET Company Participants David Hanover - IR Nimrod Ben-Natan - President & CEO Walter Jankovic - CFO Conference Call Participants Ryan Koontz - Needham & Company Steven Frankel - Rosenblatt Securities Tim Savageaux - Northland Capital Markets Simon Leopold - Raymond James George Notter - Jefferies Operator Welcome to the Third Quarter 2024 Harmonic Earnings Conference Call. My name is Josh, and I will be your operator for today's call.

Harmonic (HLIT) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.20 per share. This compares to break-even earnings per share a year ago.